Qinlock FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved May 15, 2020)
Brand name: Qinlock
Generic name: ripretinib
Dosage form: Tablets
Company: Deciphera Pharmaceuticals, Inc.
Treatment for: Gastrointestinal Stromal Tumor
Qinlock (ripretinib) is a broad-spectrum KIT and PDGFRα inhibitor for the treatment of patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Development timeline for Qinlock
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.